

## **Clinical Policy: Necitumumab (Portrazza)**

Reference Number: CP.PHAR.320

Effective Date: 03.01.17

Last Review Date: 11.21

Line of Business: HIM, Medicaid

[Coding Implications](#)  
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### **Description**

Necitumumab for injection (Portrazza™) is an epidermal growth factor receptor (EGFR) antagonist.

### **FDA Approved Indication(s)**

Portrazza is indicated in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).

Limitation(s) of use: Portrazza is not indicated for treatment of non-squamous NSCLC.

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Portrazza is **medically necessary** when the following criteria are met:

#### **I. Initial Approval Criteria**

##### **A. Non-Small Cell Lung Cancer (must meet all):**

1. Diagnosis of squamous NSCLC;
2. Prescribed by or in consultation with an oncologist;
3. Age  $\geq$  18 years;
4. Prescribed in combination with gemcitabine and cisplatin for first-line treatment of metastatic disease;
5. Request meets one of the following (a or b):\*
  - a. Dose does not exceed 800 mg on days 1 and 8 of each 3-week cycle;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 6 months**

##### **B. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid.

## II. Continued Therapy

### A. Non-Small Cell Lung Cancer (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Portrazza for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):\*
  - a. New dose does not exceed 800 mg on days 1 and 8 of each 3-week cycle;
  - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

\*Prescribed regimen must be FDA-approved or recommended by NCCN

**Approval duration: 12 months**

### B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

**Approval duration: Duration of request or 6 months (whichever is less);** or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid.

## III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid, or evidence of coverage documents.

## IV. Appendices/General Information

### Appendix A: Abbreviation/Acronym Key

EGFR: epidermal growth factor receptor  
FDA: Food and Drug Administration

NCCN: National Comprehensive Cancer  
Network

NSCLC: non-small cell lung cancer

### Appendix B: Therapeutic Alternatives

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

| Drug Name                 | Dosing Regimen   | Dose Limit/<br>Maximum Dose |
|---------------------------|--|-----------------------------|
| gemcitabine;<br>cisplatin | <p><u>Examples of Portrazza/gemcitabine/cisplatin dosing regimens:</u></p> <ul style="list-style-type: none"> <li>• <u>Portrazza pivotal trial:</u> <ul style="list-style-type: none"> <li>○ Patients were randomly assigned to gemcitabine 1250 mg/m<sup>2</sup> IV days 1 and 8, cisplatin 75 mg/m<sup>2</sup> IV day 1 +/- Portrazza 800 mg IV days 1 and 8.</li> </ul> </li> </ul> | Varies                      |

| Drug Name | Dosing Regimen   | Dose Limit/<br>Maximum Dose |
|-----------|--|-----------------------------|
|           | <ul style="list-style-type: none"> <li>• <b>Clinical Pharmacology:</b> <ul style="list-style-type: none"> <li>○ Adults: NSCLC (inoperable, locally advanced, or metastatic):                             <ul style="list-style-type: none"> <li>▪ Gemcitabine 1,000 mg/m<sup>2</sup> IV over 30 minutes followed by cisplatin 100 mg/m<sup>2</sup> IV on day 1, then gemcitabine 1,000 mg/m<sup>2</sup> IV over 30 minutes on days 8 and 15, repeated every 4 weeks.</li> <li>▪ Alternatively, gemcitabine 1,250 mg/m<sup>2</sup> IV over 30 minutes followed by cisplatin 100 mg/m<sup>2</sup> IV on day 1, then gemcitabine 1,250 mg/m<sup>2</sup> IV over 30 minutes on day 8, repeated every 3 weeks.</li> </ul> </li> </ul> </li> </ul> |                             |

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Black Box Warnings*

- Contraindications: none reported
- Black box warnings: cardiopulmonary arrest and hypomagnesemia

*Appendix D: General Information*

- The NCCN NSCLC Panel voted unanimously to delete the Portrazza/cisplatin/gemcitabine regimen from the NCCN Guidelines for patients with metastatic squamous cell NSCLC. This decision reflects the fact that the NCCN NSCLC Panel feels the addition of Portrazza to the regimen is not beneficial based on toxicity, cost, and limited improvement in efficacy when compared with cisplatin/gemcitabine. A phase 3 randomized trial only showed a slight improvement in overall survival (11.5 vs 9.9 months). In addition there were more grade 3 or higher adverse events in patients receiving the Portrazza regimen.

**V. Dosage and Administration**

| Indication     | Dosing Regimen   | Maximum Dose        |
|----------------|--|---------------------|
| Squamous NSCLC | 800 mg as an IV infusion over 60 minutes on Days 1 and 8 of each 3-week cycle prior to gemcitabine and cisplatin infusion. | 800 mg per infusion |

**VI. Product Availability**

Single-dose vial: 800 mg/50 mL (16 mg/mL)

**VII. References**

1. Portrazza Prescribing Information. Indianapolis, IN: Eli Lilly and Company; November 2015. Available at <http://uspl.lilly.com/portrazza/portrazza.html#pi>. Accessed June 22, 2021.

2. National Comprehensive Cancer Network. Non-small cell lung cancer. Version 5.2021. Available at: [http://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Accessed June 22, 2021.
3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2018. Available at: <http://www.clinicalpharmacology-ip.com/>.
4. Thatcher N, Hirsch F, Luft A, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-1 line therapy in patients with stage IV squamous nonsmall-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 study [published online ahead of print June 1, 2015]. Lancet Oncol. doi: 10.1016/S1470-2045(15)00021-2.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| HCPCS Codes | Description                  |
|-------------|------------------------------|
| J9295       | Injection, necitumumab, 1 mg |

| Reviews, Revisions, and Approvals   | Date     | P&T Approval Date |
|---|----------|-------------------|
| Policy split from CP.PHAR.182 Excellus Oncology.  | 01.17    | 03.17             |
| Policy converted to new template. Annual Review. Safety criteria was applied according to the safety guidance discussed at CPAC and endorsed by Centene Medical Affairs. Authorization limits extended from 3 and 6 months to 6 and 12 months for initial and continued approval, respectively. | 08.17    | 11.17             |
| 4Q 2018 annual review: no significant changes; HIM-Medical Benefit added; age, specialist involvement in care, continuation of care added; therapeutics alternatives table added; from previously approved corporate policy; references reviewed and updated.                                   | 08.07.18 | 11.18             |
| 4Q 2019 annual review: no significant changes; added general information stating lack of NCCN support for Portrazza based regimen; references reviewed and updated.   | 08.08.19 | 11.19             |
| 4Q 2020 annual review: no significant changes; modified HIM Medical Benefit to HIM line of business; references reviewed and updated.   | 07.22.20 | 11.20             |
| 4Q 2021 annual review: no significant changes; revised HIM.PHAR.21 to HIM.PA.154; references reviewed and updated.  | 06.22.21 | 11.21             |

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program

approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.